Literature DB >> 25293866

(68)Ga-PSMA ligand PET versus (18)F-NaF PET: evaluation of response to (223)Ra therapy in a prostate cancer patient.

Christian Uprimny1, Alexander Kroiss, Bernhard Nilica, Sabine Buxbaum, Clemens Decristoforo, Wolfgang Horninger, Irene J Virgolini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25293866     DOI： 10.1007/s00259-014-2922-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  4 in total

1.  [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.

Authors:  A Afshar-Oromieh; U Haberkorn; M Eder; M Eisenhut; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-04       Impact factor: 9.236

Review 2.  Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice.

Authors:  Nathan Lawrentschuk; Ian D Davis; Damien M Bolton; Andrew M Scott
Journal:  Int J Urol       Date:  2007-02       Impact factor: 3.369

3.  The flare phenomenon: far from fair and square.

Authors:  W D van Schelven; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1994-05

4.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245
  4 in total
  15 in total

1.  The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates.

Authors:  Lorenza Scarpa; Sabine Buxbaum; Dorota Kendler; Katharina Fink; Jasmin Bektic; Leonhard Gruber; Clemens Decristoforo; Christian Uprimny; Peter Lukas; Wolfgang Horninger; Irene Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-12       Impact factor: 9.236

2.  (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

Authors:  Francesco Ceci; Christian Uprimny; Bernhard Nilica; Llanos Geraldo; Dorota Kendler; Alexander Kroiss; Jasmin Bektic; Wolfgang Horninger; Peter Lukas; Clemens Decristoforo; Paolo Castellucci; Stefano Fanti; Irene J Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-15       Impact factor: 9.236

Review 3.  Therapy assessment of bone metastatic disease in the era of 223radium.

Authors:  Elba Etchebehere; Ana Emilia Brito; Alireza Rezaee; Werner Langsteger; Mohsen Beheshti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-31       Impact factor: 9.236

4.  Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand.

Authors:  Stefano Boschi; Jason T Lee; Seval Beykan; Roger Slavik; Liu Wei; Claudio Spick; Uta Eberlein; Andreas K Buck; Filippo Lodi; Gianfranco Cicoria; Johannes Czernin; Michael Lassmann; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-22       Impact factor: 9.236

Review 5.  18F-NaF/223RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome.

Authors:  Hossein Jadvar; Patrick M Colletti
Journal:  Br J Radiol       Date:  2018-04-16       Impact factor: 3.039

Review 6.  PSMA PET and Radionuclide Therapy in Prostate Cancer.

Authors:  Kirsten Bouchelouche; Baris Turkbey; Peter L Choyke
Journal:  Semin Nucl Med       Date:  2016-09-03       Impact factor: 4.446

7.  Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy.

Authors:  Christian Uprimny; Anna Svirydenka; Josef Fritz; Alexander Stephan Kroiss; Bernhard Nilica; Clemens Decristoforo; Roland Haubner; Elisabeth von Guggenberg; Sabine Buxbaum; Wolfgang Horninger; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-16       Impact factor: 9.236

Review 8.  Prostate-specific membrane antigen as a target for cancer imaging and therapy.

Authors:  A P Kiess; S R Banerjee; R C Mease; S P Rowe; A Rao; C A Foss; Y Chen; X Yang; S Y Cho; S Nimmagadda; M G Pomper
Journal:  Q J Nucl Med Mol Imaging       Date:  2015-07-24       Impact factor: 2.346

9.  A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer.

Authors:  Stephanie A Harmon; Ethan Bergvall; Esther Mena; Joanna H Shih; Stephen Adler; Yolanda McKinney; Sherif Mehralivand; Deborah E Citrin; Anna Couvillon; Ravi A Madan; James L Gulley; Ronnie C Mease; Paula M Jacobs; Martin G Pomper; Baris Turkbey; Peter L Choyke; M Liza Lindenberg
Journal:  J Nucl Med       Date:  2018-03-30       Impact factor: 10.057

10.  PSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT?

Authors:  Steven P Rowe; Margarita Mana-Ay; Mehrbod S Javadi; Zsolt Szabo; Jeffrey P Leal; Martin G Pomper; Kenneth J Pienta; Ashley E Ross; Michael A Gorin
Journal:  Clin Genitourin Cancer       Date:  2015-09-30       Impact factor: 2.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.